Affiliation:
1. Osaka Medical and Pharmaceutical University: Osaka Ika Yakka Daigaku
Abstract
Abstract
Objective High-grade parotid carcinoma generally has a poor prognosis, and the histological type is mucoepidermoid carcinoma (MEC), salivary duct carcinoma (SDC), carcinoma ex pleomorphic adenoma (CEPA), or adenoid cystic carcinoma (AdCC) in the majority of cases.
Methods During the 23-year period from September 1999 to December 2022, 250 patients with parotid carcinoma underwent initial treatment and had the histopathological type of their carcinoma. Retrospective study evaluated 111 MEC, SDC, CEPA, or AdCC cases among 134 patients with high-grade parotid carcinoma. We examined pathological and clinical features and prognosis, evaluated factors associated with recurrence, and performed immunohistological examinations.
Results Pathological and clinical features and factors associated with recurrence were different for each histological type. The 10-year disease-free survival rates were as follows: MEC, 34.9%; SDC, 22.6%; CEPA, 47.1%; and AdCC, 56.3%. Human epidermal growth factor receptor type-2 and androgen receptor were positive in 48% and 56% of patients with SDC, respectively, 38% and 25% of those with CEPA.
Conclusion Each histological type has its own pathological and clinical features, recurrence types, and tumor activities, suggesting that differentiating between high-grade parotid carcinomas according to histological type will improve diagnosis, and thus prognosis.
Publisher
Research Square Platform LLC
Reference35 articles.
1. Management of advanced parotid cancer. A systematic review;Jeannon JP;Eur J Surg Oncol,2009
2. Predictors of Nodal Metastasis in Parotid Malignancies: A National Cancer Data Base Study of 22,653 Patients;Xiao CC;Otolaryngol Head Neck Surg,2016
3. Prognostic scoring models in parotid gland carcinoma;Westergaard-Nielsen M;Head Neck,2021
4. El-Naggar AK, Chan JKC, Grandis JR et al (2017) World health organization classification of tumours. Chapter 7, tumours of salivary glands. IARC press, Lyon, pp 160–202
5. WHO classification of tumours editorial board. Head and neck tumours. Lyon (France): International Agency for Research on Cancer; 2022 (WHO classification of tumours series, 5th ed; vol.9)
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. 耳下腺癌pT4症例の検討;Toukeibu Gan;2023